U.S. FDA Grants Priority Review to Simeprevir TMC435 for Combination Treatment of Genotype 1 Chronic Hepatitis C Janssen Research & Development, Llc
By a News Reporter-Staff News Editor at Hepatitis Weekly -- Janssen Research & Development, LLC (Janssen) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (see also Janssen Research & Development, Llc).
Hepatitis C virus (HCV) is a blood-borne infectious disease of the liver that affects approximately 3.2 million people in the United States. When left untreated over time, HCV can cause significant damage to the liver, including cirrhosis.
"Hepatitis C is a complex disease and Janssen is committed to working with the HCV community, caregivers and healthcare systems to address this global epidemic," said Gaston Picchio, Hepatitis Disease Area Leader, Janssen Research & Development. "We are pleased that the FDA has granted simeprevir Priority Review, as it is a significant step forward in making this therapy available to physicians and their hepatitis C patients."
The FDA grants Priority Review to medicines that may offer major advances in care or provide a treatment option where no adequate therapy exists. Under the Prescription Drug User Fee Act, FDA review will begin approximately 60 days after receipt of the application and will aim to be complete within six months from when the review period begins.
The regulatory submission for simeprevir is supported in part by data from three pivotal Phase 3 studies: QUEST-1 and QUEST-2 in treatment-naive patients and PROMISE in patients who have relapsed after prior interferon-based treatment. Janssen also recently submitted simeprevir for marketing authorization to regulatory authorities in Japan and Europe.
Keywords for this news article include: Therapy, Hepatitis, Treatment, FDA Actions, Liver Diseases, Gastroenterology, Infectious Disease, Government Agencies, Offices and Entities, Digestive System Diseases, Janssen Research & Development Llc.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC